Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer

Even though frequency and patterns of IrAEs are different from pivotal studies, these results don't seem specific to older patients. Further prospective investigations are needed to better characterize and predict the impact of Nivolumab on older patients with NSCLC.